

Special Issue

Therapeutic Antibodies against Virus Infection

Message from the Guest Editors

Therapeutic monoclonal antibodies (mAbs) have become one of the fastest-growing classes of drugs in recent years and are approved for the treatment of a wide range of indications, including virus infections. Mabs and polyclonal antibodies are used for pre-exposure prophylaxis (Prep), post-exposure prophylaxis (PEP), and treatment of viral infections such as rabies, hepatitis B, SARS-CoV-2, RSV, and others. Commonly, antibody-based immunotherapies are well-tolerated, highly specific, and thus potent tools to protect from infection or a severe course of disease. Development, characterization, and pre-clinical or clinical evaluation of novel antiviral mAbs that can protect from disease is important, and articles on this topic are welcome.

Guest Editors

Dr. Adalbert Krawczyk

Department of Infectious Diseases, West German Centre of Infectious Diseases, University Duisburg-Essen, Essen, Germany

Dr. Matthias Zehner

Laboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany

Deadline for manuscript submissions

closed (31 August 2023)



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/118456

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/

[viruses](https://viruses.mdpi.com)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,
National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).